Identification of Non-Nucleoside Inhibitors of the Respiratory Syncytial Virus Polymerase Complex

Journal of Medicinal Chemistry

Volumn 60, Issue 6, 2017, Pages 2305-2325

  Jiménez Somarribas, Alberto ^a   Mao, Shuli ^a   Yoon, Jeong Joong ^b   Weisshaar, Marco ^b   Cox, Robert M ^b   Marengo, Jose R ^a   Mitchell, Deborah G ^a   Morehouse, Zachary P ^b   Yan, Dan ^b   Solis, Ivan ^b   Liotta, Dennis C ^a   Natchus, Michael G ^a   Plemper, Richard K ^b  

^a EMORY UNIVERSITY   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 METHYLFURAN 2 YL)[2 [(PHENYLAMINO)METHYL] 7,8 DIHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPIN 5(6H) YL]METHANONE; 1 [5 (3 METHYLFURAN 2 CARBONYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPIN 2 YL] 2 PHENYLETHANONE; 2 (3 METHYLFURAN 2 CARBONYL) N PHENYL 2,3,4,5 TETRAHYDRO 1H PYRROLO[1,2 A][1,4]DIAZEPINE 8 CARBOXAMIDE; 5 (1,3 DIMETHYL 1H PYRROLE 2 CARBONYL) N PHENYL 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; 5 (3 CHLOROFURAN 2 CARBONYL) N PHENYL 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; 5 (3 METHYL 1H PYRROLE 2 CARBONYL) N PHENYL 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; 5 (3 METHYLFURAN 2 CARBONYL) N (META TOLYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; 5 (3 METHYLFURAN 2 CARBONYL) N (ORTHO TOLYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; 5 (3 METHYLFURAN 2 CARBONYL) N (PARA TOLYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; 5 (3 METHYLFURAN 2 CARBONYL) N (PYRIMIDIN 4 YL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; 5 (3 METHYLFURAN 2 CARBONYL) N (PYRIMIDIN 5 YL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; 5 (3 METHYLFURAN 2 CARBONYL) N PHENYL 4,5,6,7 TETRAHYDROPYRAZOLO[1,5 A]PYRAZINE 2 CARBOXAMIDE; 5 (3 METHYLFURAN 2 CARBONYL) N PHENYL 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; 5 (3 METHYLFURAN 2 CARBONYL) N PHENYL 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 SULFONAMIDE; 5 (FURAN 2 CARBONYL) N PHENYL 5,6,7,8 TETRAHYDRO 4H PYRAZOLO [1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; N (2 CHLORO 4 FLUOROPHENYL) 5 (3 METHYLFURAN 2 CARBONYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; N (2 FLUOROPHENYL) 5 (3 METHYLFURAN 2 CARBONYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A[1,4]DIAZEPINE 2 CARBOXAMIDE; N (2 FLUOROPHENYL) 5 (FURAN 2 CARBONYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; N (2 METHOXYPHENYL) 5 (3 METHYLFURAN 2 CARBONYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; N (2,4 DIFLUOROPHENYL) 5 (3 METHYLFURAN 2 CARBONYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; N (3 FLUOROPHENYL) 5 (3 METHYLFURAN 2 CARBONYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; N (3 METHOXYPHENYL) 5 (3 METHYLFURAN 2 CARBONYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A[1,4]DIAZEPINE 2 CARBOXAMIDE; N (4 FLUOROPHENYL) 5 (3 METHYLFURAN 2 CARBONYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; N (4 METHOXYPHENYL) 5 (3 METHYLFURAN 2 CARBONYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; N BENZYL 5 (3 METHYLFURAN 2 CARBONYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPINE 2 CARBOXAMIDE; N METHYL 5 (3 METHYLFURAN 2 CARBONYL) N PHENYL 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5[1,4]DIAZEPINE 2 CARBOXAMIDE; N [5 (3 METHYLFURAN 2 CARBONYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPIN 2 YL]BENZAMIDE; N [5 (3 METHYLFURAN 2 CARBONYL) 5,6,7,8 TETRAHYDRO 4H PYRAZOLO[1,5 A][1,4]DIAZEPIN 2 YL]BENZENESULFONAMIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIVIRUS AGENT; DNA DIRECTED RNA POLYMERASE; ENZYME INHIBITOR; MOLECULAR LIBRARY; VIRAL PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SYNTHESIS; EC50; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN RESPIRATORY SYNCYTIAL VIRUS; LIVER CELL; MOUSE; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RNA SYNTHESIS; RNA VIRUS; SELECTIVITY INDEX; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DNA-DIRECTED RNA POLYMERASES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MICE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SMALL MOLECULE LIBRARIES; VIRAL PROTEINS;

EID: 85016235770     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01568     Document Type: Article

References (38)

1. Afonso, C. L.; Amarasinghe, G. K.; Banyai, K.; Bao, Y.; Basler, C. F.; Bavari, S.; Bejerman, N.; Blasdell, K. R.; Briand, F. X.; Briese, T.; Bukreyev, A.; Calisher, C. H.; Chandran, K.; Cheng, J.; Clawson, A. N.; Collins, P. L.; Dietzgen, R. G.; Dolnik, O.; Domier, L. L.; Durrwald, R.; Dye, J. M.; Easton, A. J.; Ebihara, H.; Farkas, S. L.; Freitas-Astua, J.; Formenty, P.; Fouchier, R. A.; Fu, Y.; Ghedin, E.; Goodin, M. M.; Hewson, R.; Horie, M.; Hyndman, T. H.; Jiang, D.; Kitajima, E. W.; Kobinger, G. P.; Kondo, H.; Kurath, G.; Lamb, R. A.; Lenardon, S.; Leroy, E. M.; Li, C. X.; Lin, X. D.; Liu, L.; Longdon, B.; Marton, S.; Maisner, A.; Muhlberger, E.; Netesov, S. V.; Nowotny, N.; Patterson, J. L.; Payne, S. L.; Paweska, J. T.; Randall, R. E.; Rima, B. K.; Rota, P.; Rubbenstroth, D.; Schwemmle, M.; Shi, M.; Smither, S. J.; Stenglein, M. D.; Stone, D. M.; Takada, A.; Terregino, C.; Tesh, R. B.; Tian, J. H.; Tomonaga, K.; Tordo, N.; Towner, J. S.; Vasilakis, N.; Verbeek, M.; Volchkov, V. E.; Wahl-Jensen, V.; Walsh, J. A.; Walker, P. J.; Wang, D.; Wang, L. F.; Wetzel, T.; Whitfield, A. E.; Xie, J. T.; Yuen, K. Y.; Zhang, Y. Z.; Kuhn, J. H. Taxonomy of the order mononegavirales: Update 2016 Arch. Virol. 2016, 161, 2351-2360 10.1007/s00705-016-2880-1
2. Thompson, W. W.; Shay, D. K.; Weintraub, E.; Brammer, L.; Cox, N.; Anderson, L. J.; Fukuda, K. Mortality associated with influenza and respiratory syncytial virus in the United States J. Am. Med. Assoc. 2003, 289, 179-186 10.1001/jama.289.2.179
3. Collins, P. L.; Crowe, J. E., Jr. Respiratory Syncytial Virus and Metapneumoviruses. In Fields Virology, 5th ed.; Knipe, D. M.; Howley, P. M., Eds.; Lippincott, Williams, & Wilkins: Philadelphia, PA, 2007; Vol. 2, pp 1601-1645.
4. Elliot, A. J.; Fleming, D. M. Influenza and respiratory syncytial virus in the elderly Expert Rev. Vaccines 2008, 7, 249-258 10.1586/14760584.7.2.249
5. Aherne, W.; Bird, T.; Court, S. D.; Gardner, P. S.; McQuillin, J. Pathological changes in virus infections of the lower respiratory tract in children J. Clin. Pathol. 1970, 23, 7-18 10.1136/jcp.23.1.7
6. Lugo, R. A.; Nahata, M. C. Pathogenesis and treatment of bronchiolitis Clin. Pharm. 1993, 12, 95-116
7. Domachowske, J. B.; Rosenberg, H. F. Respiratory syncytial virus infection: Immune response, immunopathogenesis, and treatment Clin. Microbiol. Rev. 1999, 12, 298-309
8. DeVincenzo, J. P.; Wilkinson, T.; Vaishnaw, A.; Cehelsky, J.; Meyers, R.; Nochur, S.; Harrison, L.; Meeking, P.; Mann, A.; Moane, E.; Oxford, J.; Pareek, R.; Moore, R.; Walsh, E.; Studholme, R.; Dorsett, P.; Alvarez, R.; Lambkin-Williams, R. Viral load drives disease in humans experimentally infected with respiratory syncytial virus Am. J. Respir. Crit. Care Med. 2010, 182, 1305-1314 10.1164/rccm.201002-0221OC
9. El Saleeby, C. M.; Bush, A. J.; Harrison, L. M.; Aitken, J. A.; Devincenzo, J. P. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children J. Infect. Dis. 2011, 204, 996-1002 10.1093/infdis/jir494
10. Anderson, L. J.; Parker, R. A.; Strikas, R. L. Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children J. Infect. Dis. 1990, 161, 640-646 10.1093/infdis/161.4.640
11. Groothuis, J. R.; Woodin, K. A.; Katz, R.; Robertson, A. D.; McBride, J. T.; Hall, C. B.; McWilliams, B. C.; Lauer, B. A. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children J. Pediatr. 1990, 117, 792-798 10.1016/S0022-3476(05)83347-5
12. Cox, R.; Plemper, R. K. Structure-guided design of small-molecule therapeutics against RSV disease Expert Opin. Drug Discovery 2016, 11, 543-556 10.1517/17460441.2016.1174212
13. Wang, G.; Deval, J.; Hong, J.; Dyatkina, N.; Prhavc, M.; Taylor, J.; Fung, A.; Jin, Z.; Stevens, S. K.; Serebryany, V.; Liu, J.; Zhang, Q.; Tam, Y.; Chanda, S. M.; Smith, D. B.; Symons, J. A.; Blatt, L. M.; Beigelman, L. Discovery of 4′-chloromethyl-2′-deoxy-3′,5′-di-o-isobutyryl-2′-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection J. Med. Chem. 2015, 58, 1862-1878 10.1021/jm5017279
14. DeVincenzo, J. P.; Whitley, R. J.; Mackman, R. L.; Scaglioni-Weinlich, C.; Harrison, L.; Farrell, E.; McBride, S.; Lambkin-Williams, R.; Jordan, R.; Xin, Y.; Ramanathan, S.; O’Riordan, T.; Lewis, S. A.; Li, X.; Toback, S. L.; Lin, S. L.; Chien, J. W. Oral GS-5806 activity in a respiratory syncytial virus challenge study N. Engl. J. Med. 2014, 371, 711-722 10.1056/NEJMoa1401184
15. Yan, D.; Lee, S.; Thakkar, V. D.; Luo, M.; Moore, M. L.; Plemper, R. K. Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors Proc. Natl. Acad. Sci. U. S. A. 2014, 111, E3441-3449 10.1073/pnas.1405198111
16. Bright, R. A.; Medina, M. J.; Xu, X.; Perez-Oronoz, G.; Wallis, T. R.; Davis, X. M.; Povinelli, L.; Cox, N. J.; Klimov, A. I. Incidence of adamantane resistance among influenza a (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern Lancet 2005, 366, 1175-1181 10.1016/S0140-6736(05)67338-2
17. Bright, R. A.; Shay, D.; Bresee, J.; Klimov, A.; Cox, N.; Ortiz, J.; Ctr, W. C.; CDC High levels of adamantane resistance among influenza a (H3N2) viruses and interim guidelines for use of antiviral agents-United States, 2005-06 influenza season J. Am. Med. Assoc. 2006, 295, 881-882 10.1001/jama.295.8.881
18. Yan, D.; Weisshaar, M.; Lamb, K.; Chung, H. K.; Lin, M. Z.; Plemper, R. K. Replication-competent influenza virus and respiratory syncytial virus luciferase reporter strains engineered for co-infections identify antiviral compounds in combination screens Biochemistry 2015, 54, 5589-5604 10.1021/acs.biochem.5b00623
19. Moore, M. L.; Chi, M. H.; Luongo, C.; Lukacs, N. W.; Polosukhin, V. V.; Huckabee, M. M.; Newcomb, D. C.; Buchholz, U. J.; Crowe, J. E., Jr.; Goleniewska, K.; Williams, J. V.; Collins, P. L.; Peebles, R. S., Jr. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction J. Virol. 2009, 83, 4185-4194 10.1128/JVI.01853-08
20. Chung, H. K.; Jacobs, C. L.; Huo, Y.; Yang, J.; Krumm, S. A.; Plemper, R. K.; Tsien, R. Y.; Lin, M. Z. Tunable and reversible drug control of protein production via a self-excising degron Nat. Chem. Biol. 2015, 11, 713-720 10.1038/nchembio.1869
21. Jacob, R. T.; Larsen, M. J.; Larsen, S. D.; Kirchhoff, P. D.; Sherman, D. H.; Neubig, R. R. Mscreen: An integrated compound management and high-throughput screening data storage and analysis system J. Biomol. Screening 2012, 17, 1080-1087 10.1177/1087057112450186
22. Brideau, C.; Gunter, B.; Pikounis, B.; Liaw, A. Improved statistical methods for hit selection in high-throughput screening J. Biomol. Screening 2003, 8, 634-647 10.1177/1087057103258285
23. Hotard, A. L.; Lee, S.; Currier, M. G.; Crowe, J. E., Jr.; Sakamoto, K.; Newcomb, D. C.; Peebles, R. S., Jr.; Plemper, R. K.; Moore, M. L. Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis J. Virol. 2015, 89, 512-522 10.1128/JVI.02472-14
24. Hawkins, E.; Butler, B.; Beck, M.; O’Grady, M.; Orr, L.; Wood, K. Dual-glo Luciferase Assay System: Convenient Dual-Reporter Measurements in 96-and 384-Well Plates. Promega Notes; Promega Corporation: Madison, WI, 2002; Vol. 81, pp 22-26.
25. Scifinder; Chemical Abstracts Service: Columbus, OH, 2015.
26. Blackburn, C.; Chin, J.; Gigstad, K. M.; Xu, H. Substituted Hydroxamic Acids and Uses Thereof. U.S. Patent No. 8,946,223, Feb 3, 2015.
27. Moussa, I. A.; Banister, S. D.; Manoli, M.; Doddareddy, M. R.; Cui, J.; MacH, R. H.; Kassiou, M. Exploration of ring size in a series of cyclic vicinal diamines with sigma1 receptor affinity Bioorg. Med. Chem. Lett. 2012, 22, 5493-5497 10.1016/j.bmcl.2012.07.026
28. Lane, J. W.; Chen, Y.; Williams, R. M. Asymmetric total syntheses of (−)-jorumycin, (−)-renieramycin g, 3-epi-jorumycin, and 3-epi-renieramycin g J. Am. Chem. Soc. 2005, 127, 12684-12690 10.1021/ja0535918
29. Tomita, N.; Hayashi, Y.; Suzuki, S.; Oomori, Y.; Aramaki, Y.; Matsushita, Y.; Iwatani, M.; Iwata, H.; Okabe, A.; Awazu, Y.; Isono, O.; Skene, R. J.; Hosfield, D. J.; Miki, H.; Kawamoto, T.; Hori, A.; Baba, A. Structure-based discovery of cellular-active allosteric inhibitors of FAK Bioorg. Med. Chem. Lett. 2013, 23, 1779-1785 10.1016/j.bmcl.2013.01.047
30. Peng, H.; Xin, Z.; Zhang, L.; Sun, L.; Kumaravel, G.; Taveras, A.; Wang, D. S1P and/or ATX Modulating Agents. US. Patent Application No. 14/772481, Feb 11, 2016.
31. Hoffman, R. V. Meta-trifluoromethylbenzenesulfonyl chloride Org. Synth. 1981, 60, 121-126 10.15227/orgsyn.060.0121
32. Blackburn, C.; Barrett, C.; Brunson, M.; Chin, J.; England, D.; Garcia, K.; Gigstad, K.; Gould, A.; Gutierrez, J.; Hoar, K.; Rowland, R. S.; Tsu, C.; Ringeling, J.; Wager, K.; Xu, H. Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform Bioorg. Med. Chem. Lett. 2014, 24, 5450-5454 10.1016/j.bmcl.2014.10.022
33. Andaloussi, M.; Lim, H. D.; van der Meer, T.; Sijm, M.; Poulie, C. B.; de Esch, I. J.; Leurs, R.; Smits, R. A. A novel series of histamine h4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: Comparison of hERG binding and target residence time with PF-3893787 Bioorg. Med. Chem. Lett. 2013, 23, 2663-2670 10.1016/j.bmcl.2013.02.091
34. Asakawa, N.; Kobayashi, S.; Goto, J.; Hirayama, N. Autogpa: An automated 3D-QSAR method based on pharmacophore alignment and grid potential analysis Int. J. Med. Chem. 2012, 2012, 1-9 10.1155/2012/498931
35. Molecular Operating Environment (MOE), 2013.08; Chemical Computing Group Inc.: Montreal, Canada, 2017; H3a 2r7.
36. Battles, M. B.; Langedijk, J. P.; Furmanova-Hollenstein, P.; Chaiwatpongsakorn, S.; Costello, H. M.; Kwanten, L.; Vranckx, L.; Vink, P.; Jaensch, S.; Jonckers, T. H.; Koul, A.; Arnoult, E.; Peeples, M. E.; Roymans, D.; McLellan, J. S. Molecular mechanism of respiratory syncytial virus fusion inhibitors Nat. Chem. Biol. 2016, 12, 87-93 10.1038/nchembio.1982
37. Hotard, A. L.; Shaikh, F. Y.; Lee, S.; Yan, D.; Teng, M. N.; Plemper, R. K.; Crowe, J. E., Jr.; Moore, M. L. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis Virology 2012, 434, 129-136 10.1016/j.virol.2012.09.022
38. Cramer, R. D.; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins J. Am. Chem. Soc. 1988, 110, 5959-5967 10.1021/ja00226a005